Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Analyst Ratings
This is a summary of current ratings and target prices for Black Diamond Therapeutics and Entrada Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Diamond Therapeutics | 1 | 2 | 8 | 0 | 2.64 |
| Entrada Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
Black Diamond Therapeutics presently has a consensus price target of $10.25, indicating a potential upside of 479.10%. Entrada Therapeutics has a consensus price target of $17.75, indicating a potential upside of 222.73%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Entrada Therapeutics.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Diamond Therapeutics | $70.00 million | 1.45 | $22.37 million | ($0.75) | -2.36 |
| Entrada Therapeutics | $4.69 million | 45.70 | -$143.75 million | ($3.96) | -1.39 |
Black Diamond Therapeutics has higher revenue and earnings than Entrada Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Black Diamond Therapeutics and Entrada Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Diamond Therapeutics | N/A | -32.10% | -25.21% |
| Entrada Therapeutics | -3,537.73% | -57.61% | -46.54% |
Institutional and Insider Ownership
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Black Diamond Therapeutics has a beta of 3.32, indicating that its stock price is 232% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.24, indicating that its stock price is 124% less volatile than the S&P 500.
Summary
Black Diamond Therapeutics beats Entrada Therapeutics on 11 of the 14 factors compared between the two stocks.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
About Entrada Therapeutics
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
